A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT05154604
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
Phase 2
Terminated
- Conditions
- Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer
- Interventions
- Drug: PlaceboDrug: SHR-1701 injection
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT05149807
- Locations
- 🇨🇳
Southern Medical University NanFang Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The Second Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, China
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
Phase 3
Not yet recruiting
- Conditions
- Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
- Interventions
- Drug: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumabDrug: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatinDrug: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 561
- Registration Number
- NCT05132413
A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
Phase 3
Terminated
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbineDrug: Capecitabine/eribulin/gemcitabine/vinorelbine
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT05134194
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT05114759
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇨🇳Shandong Cancer Hospital&Institute, Jinan, Shandong, China
🇨🇳Chongqing Cancer Hospital, Chongqi, Chongqi, China
Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis
Phase 2
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- Drug: SHR-1314 injectionDrug: placebo
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT05055934
- Locations
- 🇨🇳
Huashan Hospital of the Shanghai FuDan University, Shanghai, Shanghai, China
Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Phase 2
- Conditions
- Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
- Interventions
- Drug: SHR-1701；BP102
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT04974957
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Phase 3
Active, not recruiting
- Conditions
- Gastric or Gastroesophageal Junction Cancer
- Interventions
- Drug: SHR-1701、CAPOXDrug: Placebo、CAPOX
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 737
- Registration Number
- NCT04950322
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04924296
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SHR-1701；BP102
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT04856774
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangzhou, China
© Copyright 2025. All Rights Reserved by MedPath